HER2 and hormone receptor-positive breast cancer—blocking the right target

How to Treat Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Amplified Breast Cancer

(2009) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY